ロラタジンの世界市場

ロラタジンの世界市場は2030年までに3億4,750万米ドルに達する見込み

2024年に3億630万米ドルと推定されるロラタジンの世界市場は、2024年から2030年にかけてCAGR 2.1%で成長し、2030年には3億4,750万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである錠剤は、CAGR 2.0%を記録し、分析期間終了時には1億5,600万米ドルに達すると予測されます。CAGRは2.7%です。

米国市場は8,340万米ドルと推定、中国はCAGR 4.0％で成長すると予測

米国のロラタジン市場は2024年に8,340万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに6,500万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9％と1.8％と予測されています。欧州では、ドイツがCAGR 1.2%で成長すると予測されています。

世界のロラタジン市場- 主要動向と促進要因まとめ

ロラタジンとは何か、なぜアレルギー管理に広く使われているのか？

ロラタジンは、アレルギー性鼻炎（花粉症）、蕁麻疹（じんましん）、その他の皮膚アレルギーや呼吸器アレルギーの症状を治療するために一般的に使用される第二世代の抗ヒスタミン薬です。くしゃみ、鼻水、目のかゆみ、皮膚の発疹などのアレルギー症状を引き起こす体内物質であるヒスタミンの働きを阻害することで効果を発揮します。第一世代の抗ヒスタミン薬とは異なり、ロラタジンは鎮静作用がないため、特に働き盛りの大人や子供の日中の使用に非常に適しています。錠剤、シロップ剤、口腔内崩壊錠など様々な剤形があり、世界的に数多くのブランド名で販売されているが、中でもクラリチンは最も認知度が高いです。

多くの国で一般用医薬品（OTC）として販売されているため、消費者は処方箋を必要とせず、軽度から中等度のアレルギー症状を自己管理することができ、その人気はさらに高まっています。ロラタジンはまた、症状緩和のために、充血除去薬やコルチコステロイド薬との併用療法にも多く用いられています。季節性アレルギーの増加、環境汚染、室内アレルゲンへの過敏性により、ロラタジンは世界的に安定した需要を維持しており、小売薬局とヘルスケアプロバイダーの両方のチャネルにおいて、抗ヒスタミン薬クラスの定番となっています。

どのような市場動向とイノベーションがロラタジンの状況を形成しているか？

ロラタジン市場は、使いやすい製剤、併用療法、ジェネリック代替品への需要の高まりとともに進化しています。特に小児や高齢者向けに、利便性と作用発現性を向上させるため、速溶錠や液状ゲルへのシフトが進んでいます。製薬会社はまた、ロラタジンとプソイドエフェドリン（うっ血除去剤）を組み合わせたデュアルアクション製品を開発し、1回の服用でアレルギーと副鼻腔の両方の症状を治療することで、複数の上気道愁訴を抱える消費者のニーズに応えています。

さらに、先発品の特許が切れたことで、費用対効果の高いジェネリック医薬品の生産と入手が急増し、新興市場における購入しやすさと入手しやすさが向上しています。フェキソフェナジンやレボセチリジンのような新しい抗ヒスタミン薬が入手可能であるにもかかわらず、眠くならず、長時間持続するアレルギー症状の緩和を求める消費者の嗜好は、ロラタジンの競争力を維持しています。eコマース・チャンネルと遠隔医療プラットフォームは、市場の裾野をさらに広げ、簡単な購入とデジタル処方箋の配達を可能にしています。さらに、ドラッグデリバリーシステムの研究開発により、徐放性製剤や経鼻製剤が市場に投入され、治療上の有用性が多様化し、患者の服薬アドヒアランスが向上すると期待されています。

世界のロラタジン市場の成長を促進する要因は？

世界のロラタジン市場の成長は、アレルギー疾患の発生率の増加、OTC医薬品セグメントの拡大、非鎮静性抗ヒスタミン薬に対する認識の高まりなど、いくつかの要因によって牽引されています。都市化、大気汚染、気候変動の激化に伴い、季節性・通年性アレルギーの有病率は上昇傾向にあり、より多くの消費者が信頼性が高く即効性のある症状緩和を求めています。ロラタジンの安全性プロファイルと長年にわたって確立された有効性により、自己投薬と医師による処方箋の両方で、この医薬品は頼りになる選択肢となっています。

もうひとつの重要な成長要因は、特にアジア太平洋、ラテンアメリカ、アフリカの一部のコストに敏感なヘルスケア市場におけるジェネリック医薬品への需要の高まりです。このため、製薬会社は地域的なパートナーシップや規制当局の承認を通じて、ロラタジンの生産と流通を拡大しようとしています。新興経済諸国におけるヘルスケア支出の増加、アレルギー症状に対する意識の高まり、保険適用範囲の拡大も販売量を押し上げています。さらに、ロラタジンが国の必須医薬品リストや公衆衛生プログラムに掲載されたことで、基本的なアレルギー治療プロトコールにおけるロラタジンの重要性が強化され、世界市場の持続的かつ広範な成長に寄与しています。

セグメント

剤形（錠剤、カプセル剤、シロップ剤、その他の剤形）;グレード（USP標準グレード、EP標準グレード、医薬品標準グレード、その他のグレード）;エンドユース（小売薬局、病院薬局、オンライン薬局）

調査対象企業の例

• Apotex Inc.
• Bayer AG
• Cadila Pharmaceuticals
• Dr. Reddy's Laboratories
• Glenmark Pharmaceuticals
• Hetero Drugs Limited
• Lupin Limited
• Merck & Co., Inc.
• Morepen Laboratories Ltd.
• Mylan N.V.
• Perrigo Company plc
• Pfizer Inc.
• Ranbaxy Laboratories Ltd.
• Schering-Plough（now part of Merck）
• Sun Pharmaceutical Industries Ltd.
• Taro Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Wockhardt Ltd.
• Zydus Cadila

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Loratadine Market to Reach US$347.5 Million by 2030

The global market for Loratadine estimated at US$306.3 Million in the year 2024, is expected to reach US$347.5 Million by 2030, growing at a CAGR of 2.1% over the analysis period 2024-2030. Tablets, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$156.0 Million by the end of the analysis period. Growth in the Capsules segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$83.4 Million While China is Forecast to Grow at 4.0% CAGR

The Loratadine market in the U.S. is estimated at US$83.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$65.0 Million by the year 2030 trailing a CAGR of 4.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Loratadine Market - Key Trends & Drivers Summarized

What Is Loratadine and Why Is It Widely Used in Allergy Management?

Loratadine is a second-generation antihistamine commonly used to treat symptoms of allergic rhinitis (hay fever), urticaria (hives), and other skin or respiratory allergies. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms such as sneezing, runny nose, itchy eyes, and skin rashes. Unlike first-generation antihistamines, loratadine is non-sedating, making it highly favorable for daytime use, especially among working adults and children. It is available in various forms including tablets, syrups, and orally disintegrating tablets, and is marketed under numerous brand names globally, with Claritin being among the most recognized.

Its over-the-counter (OTC) availability in many countries has further boosted its popularity, allowing consumers to self-manage mild to moderate allergy symptoms without needing a prescription. Loratadine is also included in numerous combination therapies with decongestants or corticosteroids for enhanced symptom relief. The increasing prevalence of seasonal allergies, environmental pollution, and sensitivity to indoor allergens has maintained consistent global demand for loratadine, making it a staple in the antihistamine drug class within both retail pharmacy and healthcare provider channels.

What Market Trends and Innovations Are Shaping the Loratadine Landscape?

The loratadine market is evolving with the rising demand for user-friendly formulations, combination therapies, and generic alternatives. There has been a growing shift toward fast-dissolving tablets and liquid gels to improve convenience and onset of action, particularly for pediatric and geriatric populations. Pharmaceutical companies are also developing dual-action products that combine loratadine with pseudoephedrine (a decongestant) to treat both allergy and sinus symptoms in a single dose-catering to the needs of consumers with multiple upper respiratory complaints.

Additionally, the expiration of original patents has led to a surge in the production and availability of cost-effective generic versions, increasing affordability and accessibility in emerging markets. Consumer preferences for non-drowsy, long-lasting allergy relief have kept loratadine competitive despite the availability of newer antihistamines like fexofenadine or levocetirizine. E-commerce channels and telehealth platforms have further expanded the market’s reach, enabling easy purchase and digital prescription fulfillment. Moreover, ongoing R&D in drug delivery systems is expected to bring extended-release and intranasal loratadine formulations to market, diversifying its therapeutic utility and improving patient adherence.

What Factors Are Driving Growth in the Global Loratadine Market?

The growth in the global loratadine market is driven by several factors, including increasing incidence of allergic conditions, the expanding OTC pharmaceutical segment, and the growing awareness of non-sedating antihistamines. As urbanization, air pollution, and climate variability intensify, the prevalence of seasonal and perennial allergies is on the rise, leading more consumers to seek reliable, fast-acting symptom relief. Loratadine’s safety profile and long-established efficacy make it a go-to option for both self-medication and physician-prescribed regimens.

Another key growth driver is the rising demand for generic drugs, particularly in cost-sensitive healthcare markets across Asia-Pacific, Latin America, and parts of Africa. This is encouraging pharmaceutical companies to expand loratadine production and distribution through regional partnerships and regulatory approvals. Increased healthcare spending, higher awareness of allergy symptoms, and broader insurance coverage in developing economies are also boosting sales volume. Additionally, the inclusion of loratadine in national essential medicines lists and public health programs reinforces its importance in basic allergy treatment protocols, contributing to sustained and widespread global market growth.

SCOPE OF STUDY:

The report analyzes the Loratadine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Form (Tablets, Capsules, Syrups, Other Forms); Grade (USP Standard Grade, EP Standard Grade, Medicine Standard Grade, Other Grades); End-Use (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Apotex Inc.
• Bayer AG
• Cadila Pharmaceuticals
• Dr. Reddy's Laboratories
• Glenmark Pharmaceuticals
• Hetero Drugs Limited
• Lupin Limited
• Merck & Co., Inc.
• Morepen Laboratories Ltd.
• Mylan N.V.
• Perrigo Company plc
• Pfizer Inc.
• Ranbaxy Laboratories Ltd.
• Schering-Plough (now part of Merck)
• Sun Pharmaceutical Industries Ltd.
• Taro Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Wockhardt Ltd.
• Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Loratadine - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Allergic Rhinitis and Seasonal Allergies Drives Demand for Loratadine-Based Therapies
  • Increased Availability of Loratadine as an OTC Drug Expands Consumer Access and Market Penetration
  • Growing Preference for Non-Sedating Antihistamines Strengthens Loratadines Competitive Position
  • Expansion of Self-Care and Self-Medication Trends Spurs Demand for Oral Allergy Treatments
  • Favorable Safety Profile and Minimal Side Effects Sustain Long-Term Use Across Age Groups
  • Growing Geriatric Population With Respiratory Sensitivities Expands Addressable Market
  • Increased Online Pharmacy and E-Commerce Sales Channels Broaden Distribution Reach
  • Combination Formulations with Decongestants and Nasal Sprays Enhance Market Differentiation
  • Strong Generic Drug Penetration Encourages Competitive Pricing and Volume-Driven Growth
  • Expanding Access in Emerging Economies Supports Wider Adoption of Affordable Allergy Medications
  • Pediatric Allergy Market Growth Boosts Use of Syrup and Chewable Loratadine Formulations
  • Changing Climatic Conditions and Rising Pollution Levels Drive Up Incidences of Allergic Reactions
  • Hospital and Clinic Recommendations for OTC Antihistamines Promote Brand Trust and Uptake
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Loratadine Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Loratadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Loratadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Loratadine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Tablets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Capsules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Syrups by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Syrups by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Syrups by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for USP Standard Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for USP Standard Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for USP Standard Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for EP Standard Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for EP Standard Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for EP Standard Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Medicine Standard Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Medicine Standard Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Medicine Standard Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Grades by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Grades by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Grades by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• JAPAN
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• CHINA
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• EUROPE
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Loratadine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Loratadine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Loratadine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• FRANCE
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• GERMANY
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Loratadine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Loratadine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Loratadine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• INDIA
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Loratadine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Loratadine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Loratadine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Loratadine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Loratadine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Loratadine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030
• AFRICA
  • Loratadine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Loratadine by Form - Tablets, Capsules, Syrups and Other Forms Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Loratadine by Form - Percentage Breakdown of Value Sales for Tablets, Capsules, Syrups and Other Forms for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Loratadine by End-Use - Hospital Pharmacies, Online Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Loratadine by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies, Online Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Loratadine by Grade - USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Loratadine by Grade - Percentage Breakdown of Value Sales for USP Standard Grade, EP Standard Grade, Medicine Standard Grade and Other Grades for the Years 2015, 2025 & 2030

IV. COMPETITION